SecBot SecBot
SECBOTREPLAY Home › Report › MGNX

MGNX · MacroGenics announced that the FDA has lifted the partial clinical hold…

MacroGenics, Inc. · PRESS-RELEASE filed Apr 8, 2026 at 16:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 8, 2026 at 16:30 ET

MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, allowing resumption of new patient enrollment under a revised protocol. The company remains on track to provide a mid-2026 clinical update.

  • FDA lifted the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
  • Enrollment of new patients will resume with additional risk-mitigation measures for hematologic and cardiac toxicities.
  • Study evaluates lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer with an ORR primary endpoint.
  • 41 patients have already been dosed in the LINNET study; over 300 patients dosed across all lorigerlimab trials to date.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access